Kairos Pharma Ltd (AMEX: KAPA) is -70.39% lower on its value in year-to-date trading and has touched a low of $0.52 and a high of $4.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The KAPA stock was last observed hovering at around $0.59 in the last trading session, with the day’s loss setting it -0.14%.
Currently trading at $0.45, the stock is -28.21% and -44.18% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 10.17 million and changing -23.51% at the moment leaves the stock -65.28% off its SMA200. KAPA registered a loss of -72.73% in past 6-months. The firm has a 50-day simple moving average (SMA 50) of $0.8174 and a 200-day simple moving average (SMA200) of $1.3009944.
The stock witnessed a -44.67% gain in the last 1 month and extending the period to 3 months gives it a -59.09%, and is -29.58% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 15.20% over the week and 7.75% over the month.
Kairos Pharma Ltd (KAPA) has around 4 employees, a market worth around $7.58M and $0.00M in sales. Distance from 52-week low is -13.68% and -88.75% from its 52-week high. The company has generated returns on investments over the last 12 months (-49.66%).
The EPS is expected to grow by 7.25% this year.
Kairos Pharma Ltd (KAPA) Top Institutional Holders
8.0 institutions hold shares in Kairos Pharma Ltd (KAPA), with institutional investors hold 17.75% of the company’s shares. The shares outstanding are 15.83M, and float is at 7.12M with Short Float at 1.20%. Institutions hold 9.36% of the Float.
Kairos Pharma Ltd (KAPA) Insider Activity
The most recent transaction is an insider purchase by Murali Ramachandran,the company’sVP of Research and Development. SEC filings show that Murali Ramachandran bought 200 shares of the company’s common stock on Nov 25 ’24 at a price of $1.59 per share for a total of $318.0. Following the purchase, the insider now owns 0.13 million shares.
Kairos Pharma Ltd disclosed in a document filed with the SEC on Nov 22 ’24 that Samuelson Doug (Chief Financial Officer) bought a total of 2,500 shares of the company’s common stock. The trade occurred on Nov 22 ’24 and was made at $1.50 per share for $3750.0. Following the transaction, the insider now directly holds 60796.0 shares of the KAPA stock.
Still, SEC filings show that on Nov 20 ’24, Yu John S (CEO and Chairman) acquired 4,000 shares at an average price of $1.44 for $5760.0. The insider now directly holds 5,341,837 shares of Kairos Pharma Ltd (KAPA).
